<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9639">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05693766</url>
  </required_header>
  <id_info>
    <org_study_id>VICCBRE2256</org_study_id>
    <nct_id>NCT05693766</nct_id>
  </id_info>
  <brief_title>Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort</brief_title>
  <acronym>INSIGHT</acronym>
  <official_title>Integrating Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (INSIGHT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sonya Reid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agendia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Susan G. Komen Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the&#xD;
      impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal&#xD;
      A hormone receptor-positive (HR+) metastatic breast cancer (MBC)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - Determine the impact of early chemotherapy (i.e., capecitabine) versus endocrine&#xD;
      therapy-based regimen on anti-tumor effect in patients with non-Luminal A hormone&#xD;
      receptor-positive (HR+) metastatic breast cancer&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  Compare the safety and tolerability of capecitabine versus endocrine therapy in patients&#xD;
           with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer&#xD;
&#xD;
        -  Determine the impact of early chemotherapy (i.e., capecitabine) versus endocrine&#xD;
           therapy-based regimen on anti-tumor effect in patients with non-Luminal A hormone&#xD;
           receptor-positive (HR+) metastatic breast cancer&#xD;
&#xD;
      Correlatives:&#xD;
&#xD;
        -  Determine if the tumor mutations detected in cfDNA are early surrogates of response&#xD;
&#xD;
        -  Determine if the cfDNA results at disease progression show new genomic alterations&#xD;
           potentially associated with resistance to therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2023</start_date>
  <completion_date type="Anticipated">May 30, 2037</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 2 years</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 5 years</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 10 years</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Percentage of patients without disease progression at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 28 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall impact of treatment toxicity</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be measured using Functional Assessment of Cancer Therapy (FACT)-G (5 point Likert-type scale from 1 (&quot;none at all&quot;) to 5 (&quot;very much&quot;)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Invasive Mammary Carcinoma</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Physician's Choice of Endocrine-based Therapy_Non-Luminal A subtypes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine_Non-Luminal A subtypes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000 mg taken by mouth twice daily for 7 days on, 7 days off</description>
    <arm_group_label>Capecitabine_Non-Luminal A subtypes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endocrine-therapy</intervention_name>
    <description>Endocrine therapy administered</description>
    <arm_group_label>Physician's Choice of Endocrine-based Therapy_Non-Luminal A subtypes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MammoPrint ® and BluePrint assays</intervention_name>
    <description>Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays</description>
    <arm_group_label>Capecitabine_Non-Luminal A subtypes</arm_group_label>
    <arm_group_label>Physician's Choice of Endocrine-based Therapy_Non-Luminal A subtypes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated written informed consent.&#xD;
&#xD;
          -  Subjects ≥ 18 years of age.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          -  Clinical stage IV invasive mammary carcinoma or unresectable locoregional recurrence&#xD;
             of invasive mammary carcinoma that is:&#xD;
&#xD;
               -  ER/PR-positive (&gt; 1% cells) by IHC and HER2 negative (by IHC or FISH)&#xD;
&#xD;
               -  Previously progressed on an aromatase inhibitor (AI) or a selective&#xD;
                  estrogenreceptor modulator/ downregulator (SERM; SERD) + a CDK4/6 inhibitor&#xD;
&#xD;
               -  Appropriate candidates for chemotherapy&#xD;
&#xD;
               -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors&#xD;
                  (RECIST) version 1.1 criteria that has not been previously irradiated and which&#xD;
                  can be followed by CT or MRI.&#xD;
&#xD;
          -  Adequate organ function including:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L&#xD;
&#xD;
               -  Platelets ≥ 100 × 10^9/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9/g/dL (may have been transfused)&#xD;
&#xD;
               -  Total serum bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤&#xD;
                  2.5 × ULN (or ≤ 5 × ULN if liver metastases are present)&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 50mL/min as&#xD;
                  calculated using the Cockcroft-Gault (CG) equation&#xD;
&#xD;
          -  For randomized patients only: tumors must be diagnosed as non-Luminal A using the&#xD;
             Blueprint® and Mammaprint® tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PIK3CA mutation&#xD;
&#xD;
          -  Prior chemotherapy in the metastatic setting&#xD;
&#xD;
          -  More than 1 line of prior endocrine therapy in the metastatic setting&#xD;
&#xD;
          -  Radiation therapy ≤ 2 weeks prior to study entry. Patients who have received prior&#xD;
             radiotherapy must have recovered from toxicity (≤ grade 1) induced by this treatment&#xD;
             (except for alopecia)&#xD;
&#xD;
          -  Previous malignant disease other than breast cancer within the last 5 years, with the&#xD;
             exception of basal or squamous cell carcinoma of the skin, cervical carcinoma in situ,&#xD;
             or low-risk cancers considered curatively treated (i.e. complete remission achieved at&#xD;
             least 2 years prior to first dose of study drugs AND additional therapy not required&#xD;
             while receiving study treatment).&#xD;
&#xD;
          -  Symptomatic brain metastases (patients with a history of brain metastases must be&#xD;
             clinically stable for more than 4 weeks from completion of radiation treatment and off&#xD;
             steroids)&#xD;
&#xD;
          -  Persisting toxicity related to prior therapy that has not reduced to Grade 1 [National&#xD;
             Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5.0];&#xD;
             however, alopecia and sensory neuropathy Grade ≤ 2 is acceptable.&#xD;
&#xD;
          -  Pregnant or breastfeeding females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonya Reid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University/Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanderbilt-Ingram Services for Timely Access</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Sonya Reid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2023</verification_date>
  <study_first_submitted>January 11, 2023</study_first_submitted>
  <study_first_submitted_qc>January 11, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2023</study_first_posted>
  <last_update_submitted>June 1, 2023</last_update_submitted>
  <last_update_submitted_qc>June 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Sonya Reid</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 16, 2023</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT05693766/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

